Prenatal microarray analysis as second‐tier diagnostic test: single‐center prospective study

ABSTRACT Objective To evaluate the usefulness of chromosome microarrays as a second‐tier test in prenatal genetic testing. Methods We prospectively analyzed 75 high‐risk pregnancies undergoing invasive prenatal genetic testing in which the karyotype either was normal or had findings other than a com...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ultrasound in obstetrics & gynecology 2013-03, Vol.41 (3), p.267-273
Hauptverfasser: Schmid, M., Stary, S., Springer, S., Bettelheim, D., Husslein, P., Streubel, B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ABSTRACT Objective To evaluate the usefulness of chromosome microarrays as a second‐tier test in prenatal genetic testing. Methods We prospectively analyzed 75 high‐risk pregnancies undergoing invasive prenatal genetic testing in which the karyotype either was normal or had findings other than a common non‐mosaic autosomal aneuploidy. Results Chromosomal microarray analysis (CMA) was performed successfully in all cases. Pathological copy‐number variations (CNVs) explaining the phenotypes were found in 11 cases (14.7%). Four cases were detected with an unbalanced translocation. In three of these cases, subsequent genetic analysis demonstrated that a parent was an unknown carrier of a balanced translocation. Among the 67 cases with normal karyo‐types, submicroscopic rearrangements with pathological significance were detected in five (7.5%) and CNVs of unclear significance were detected in one (1.5%). CMA was able to discriminate correctly between true mosaicism and confined or pseudomosaicism in all six mosaic cases. Conclusion CMA is a valuable second‐tier test in high‐risk pregnancies for which identification or further delineation of genetic aberrations is important. Its higher resolution results in a higher detection rate of aberrant cases, with a clear clinical benefit for estimation of risk of recurrence. Copyright © 2013 ISUOG. Published by John Wiley & Sons, Ltd.
ISSN:0960-7692
1469-0705
DOI:10.1002/uog.12389